Inventory

9 Months Ended

Sep. 30, 2022

The components of inventory are summarized as follows:


(In millions)	As of September 30, 2022		As of December 31, 2021
Raw materials	$	394.2	$	349.6
Work in process(1)	771.0		814.0
Finished goods	209.8		187.9
Total inventory	$	1,375.0	$	1,351.5

(1) Work in process inventory as of September 30, 2022, includes approximately $118.0 million related to lecanemab.

In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer’s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0 million of inventory related to

ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income for the nine months ended September 30, 2022. We have recognized approximately $136.0 million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the nine months ended September 30, 2022.

During the fourth quarter of 2021 we wrote-off approximately $120.0 million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income for the year ended December 31, 2021. We have recognized approximately $59.0 million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.

As of September 30, 2022, the carrying value of our ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0 million of ADUHELM inventory. For additional information please read Note 18, Collaborative and Other Relationships, to these condensed consolidated financial statements.